Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coenzyme Q10 (ubidecarenone) is a naturally occurring fat-soluble quinone that acts as a critical component of the mitochondrial electron transport chain, facilitating the production of ATP. It also serves as a potent antioxidant, protecting cell membranes and lipoproteins from oxidative damage. Shenyang Dashan Pharmaceutical Technology is developing an oral tablet formulation of coenzyme Q10 primarily for the treatment of cardiovascular diseases, where it is thought to improve myocardial energetics and reduce oxidative stress. While widely available as a dietary supplement, it is also regulated as a pharmaceutical product in various jurisdictions for indications such as heart failure and mitochondrial disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ubidecarenone.